KayoThera, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
KayoThera, Inc. - overview
Established
2019
Location
Seattle, WA, US
Primary Industry
Biotechnology
About
Based in New Jersey, US, and founded in 2019 by its Vice-president, Mark Esposito, and scientific advisory board member Yibin Kang, KayoThera, Inc. , operates as a biotechnology company that develops immuno- and targeted therapies to cure cancer. In March 2022, KayoThera, Inc. raised series A funding from Accelerator Life Science Partners, with participation from BioAdvance.
New investors Pier 70 Ventures, and WRF Capital. , and received an expanded financing in July 2023. As of 2023, Thong Q. Le acts as the President and CEO of the company.
KayoThera offers therapies to treat late-stage and metastatic cancers, including breast, lung, pancreatic, colorectal, brain, and kidney cancers. The company intends to use the July 2023 funding to accelerate product development programs in diabetes and oncology.
Current Investors
BioAdvance, Accelerator Life Science Partners, 7G BioVentures
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Oncology/Cancer Treatment
Website
www.kayothera.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.